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ABSTRACT
A graft-versus-tumor effect through nonmyeloablative allogeneic stem cell transplantation (N-SCT) in met-
astatic renal cell carcinoma (RCC) has been reported. An Intergroup phase II trial was undertaken to define
further the feasibility, toxicity and efficacy of this approach in a multi-institutional setting, Patients with
cytokine-refractory, metastatic RCC were treated with N-SCT. The conditioning regimen was fludarabine 30
mg · m2 · d1 on day (d) 7 through d 3 and cyclophosphamide 60 mg · kg1 · d1 on d 4 and d 3.
Patients received 2-8 106 CD34 cells/kg of granulocyte colony-stimulating factor mobilized stem cells from
a 6/6 HLA-matched sibling donor. Immunosuppression after transplantation included tacrolimus and meth-
otrexate. Twenty-two patients were enrolled at 14 institutions. Greater than 90% donor T-cell chimerism was
observed in 17 of 19 evaluable patients (89%) by d 120. No objective response was observed. Acute
graft-versus-host disease (GVHD) was observed in 11 patients (50%). Chronic GVHD was reported in 5
patients (23%). There was 1 patient death from liver failure secondary to chronic GVHD. Regimen-related
mortality was 2 of 22 (9%; liver failure, sepsis). Median survival time was 5.5 months (95% confidence interval,
3.9-12.0 months) and the median time to progression was 3.0 months (95% confidence interval, 2.3-4.2
months). N-SCT for metastatic RCC is feasible in a multi-institutional setting. Adequate donor T-cell
engraftment was achieved in most patients before disease progression. A graft-versus-tumor effect was not
observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding
of this approach. Allogeneic SCT remains investigational in RCC.
© 2006 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Metastatic renal cell carcinoma (RCC) currently
s a largely incurable disease with few effective
reatment options. Immunotherapy including inter-
he content of this report is solely the responsibility of the authors and does
lot necessarily represent the ofﬁcial views of the National Cancer Institute.
78eukin-2 and/or interferon- is standard initial treat-
ent in metastatic RCC, but these agents have limited
ffects on RCC tumor progression in most patients
1]. Investigators have thus attempted to improve on
mmunotherapy in a myriad of ways including combina-
ion cytokine therapy [2,3], administration of immuno-
ogically active cells such as lymphokine-activated killer
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Allogeneic Transplantation in Renal Carcinoma 779ells [4,5], or tumor-inﬁltrating lymphocytes [6]. Each of
hese strategies sought to generate an antitumor immune
esponse, but none resulted in signiﬁcant clinical beneﬁt.
nvestigation into alternative forms of inducing an anti-
umor immune response in RCC is thus warranted.
One such immunotherapeutic maneuver that has
een applied to metastatic RCC is nonmyeloablative
llogeneic stem cell transplantation (N-SCT). This
rocedure involves administration of an immunosup-
ressive conditioning regimen that allows for engraft-
ent of blood or bone marrow stem cells from a
istocompatible donor. Donor T lymphocytes recog-
ize recipient tissue antigens as foreign and generate a
raft-versus-host (GVH) reaction called GVH disease
GVHD). GVHD results in inﬂammation in target
rgans, primarily skin, liver, and gastrointestinal tract.
VHD can be accompanied by a graft-versus-tumor
GVT) effect due to the recognition of host tumor
ells by donor cells as foreign and can result in recip-
ent tumor regression. N-SCT has been described for
etastatic RCC using mainly sibling donors with pre-
iminary evidence of antitumor activity in several sin-
le institution studies (Table 1) [7-15]. Of note, these
tudies enrolled patients with nonuniform baseline
haracteristics, employed variable conditioning and
mmunosuppression regimens after transplantation,
nd included small patient numbers. It may be sur-
ised from these series, however, that a graft-versus-
CC effect can be induced by N-SCT and is balanced
gainst toxicity including GVHD and transplant-
elated mortality. The limitations of these studies
ave hampered the ability to precisely estimate the
elative risks and beneﬁts of this approach in met-
static RCC.
Based on these considerations, a study of N-SCT
n metastatic RCC was undertaken to deﬁne the fea-
ibility, safety, and efﬁcacy of this approach when
erformed in a multi-institutional setting.
able 1. Major Series of Sibling Donor, Nonmyeloablative Allogeneic
tem Cell Transplantation in Metastatic Renal Cell Carcinoma
Study
Patients,
n
Objective
Response
Rate* GVHD† TRM‡
hilds et al [7] 19 53% 74% 12%
ini et al [8], Artz
et al [9] 18 22% 50% 14%
regni et al [10] 7 57% 86% 0%
edrazolli et al [11] 7 0% 0% 29%
eno et al [12] 15 20% 60% 20%
akagawa et al [13] 9 11% 56% 0%
assenkeil et al [14] 6 33% 67% 0%
ykodi et al [15] 8 13% 63% 0%
Complete or partial tumor response.
Percentage of patients with acute and/or chronic GVHD.
Transplant-related mortality deﬁned as non–disease-related pa-htient deaths before day 100.ETHODS
Eligible patients had histologically conﬁrmed meta-
tatic RCC of clear cell or papillary subtype with mea-
urable disease as deﬁned by Response Evaluation Cri-
eria in Solid Tumors (RECIST) criteria [16]. Patients
ust have received previous therapy for metastatic RCC
onsisting of interluekin-2 and/or interferon- with dis-
ase progression or intolerance of therapy. Other previ-
us systemic therapy was permitted but not required.
atient age 60 years, life expectancy 6 months, and
astern Cooperative Oncology Group (ECOG) perfor-
ance status of 0 or 1 were required. An HLA-identical
ibling donor was required. Patients had normal organ
nd marrow function as deﬁned by a granulocyte count
1500/L, platelet count 100 000/L, total bilirubin
evel2 institutional upper limit of normal, aspartate
minotransferase level 3  institutional upper limit of
ormal, and creatinine clearance 40 mL/min (calcu-
ated by Cockcroft-Gault formula). Adequate cardiac
unction as deﬁned by a left ventricular ejection fraction
45% by echocardiogram or Multiple Gated Acquisi-
ion Scan and adequate pulmonary function as deﬁned
y Diffusion Capacity of the Lung for Carbon Monox-
de 40% of expected value corrected for hemoglobin
evel were required.
Patients who had received any systemic therapy
or RCC within 4 weeks or radiotherapy within 2
eeks before entering the study were excluded. Pa-
ients with any current or previous central nervous
ystem metastases were excluded. All patients under-
ent brain magnetic resonance imaging before enroll-
ent to exclude central nervous system metastatic dis-
ase. Patients with uncontrolled diabetes, active serious
nfection, pregnancy/nursing, known hypersensitivity to
scherichia coli-derived product, or known positivity for
uman immunodeﬁciency virus were excluded. Patients
ere not permitted to have a currently active second
alignancy. Second malignancies were not considered
urrently active if the patient had completed therapy and
as considered to be at 30% risk of relapse. All pa-
ients signed a written protocol-speciﬁc informed con-
ent approved by their institutional review board.
Sibling donors were HLA-identical (6/6) by sero-
ogic typing (for class 1 antigens) and molecular typing
for class 2 antigens). Syngeneic donors, 6/6 sibling
onors, matched unrelated donors, and haploidentical
onors were excluded. All donors were healthy and
et each bone marrow transplantation center institu-
ional requirements for stem cell donation including
esting for human immunodeﬁciency virus, hepatitis,
nd syphilis. Donors received granulocyte colony-
timulating factor (Neupogen, Amgen, Thousand
aks, Calif) before leukapheresis and had no signiﬁ-
ant cardiopulmonary, renal, endocrine, or hepatic
isease. In addition, donors could not be pregnant or
ave a previous malignancy except nonmelanoma skin
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B. I. Rini et al780ancer, cervical carcinoma in situ, superﬁcial bladder
ancer, or stage I or II cancer that was adequately
reated and currently in remission. All donors signed a
ritten protocol-speciﬁc informed consent approved
y their institutional review board.
reatment
Patients received a conditioning regimen consisting
f ﬂudarabine 30 mg · m2 · d1 intravenously (IV) on
ay (d) 7 (7 days before stem cell infusion) through d
3 and cyclophosphamide 60 mg · kg1 · d1 IV on d
4 and d3 based on previous experience with a similar
onditioning regimen in RCC [7]. Chemotherapy doses
ere based on corrected body weight, calculated as .25
(actual weight  ideal weight)  ideal weight]. Alloge-
eic peripheral blood stem cells were infused at a dose of
-8 106 CD34 cells/kg (recipient actual weight) on d
. Patients received granulocyte colony-stimulating fac-
or 5 g/kg subcutaneously starting on d 5 and con-
inued until an absolute neutrophil count of .5  109/L
as maintained for 3 consecutive days.
heresis of Allogeneic Donors
Stem cell donors received granulocyte colony-
timulating factor 10 g · kg1 · d1 on d5 through
2 (and, if necessary, d 1). Beginning on day 1,
aily vein-to-vein apheresis was performed on the
onor to harvest peripheral blood stem cells until
-8  106 CD34 cells/kg recipient body weight was
chieved. An additional 6  107 donor CD3 cells/kg
ere allowed to be collected, frozen in 2 separate
liquots (1  107and 5  107 CD3 cells/kg), and
tored in liquid nitrogen for possible subsequent do-
or lymphocyte infusion (DLI).
VHD Prophylaxis
Tacrolimus (FK506, Prograf; Astellas Pharma Inc,
eerﬁeld, IL) was administered orally (or IV, if not
olerated) beginning on d 1 to maintain a serum
rough level of 5-10 ng/mL. Tacrolimus was tapered
ver 30 days beginning on d 60 in the absence of
VHD. Patients with disease progression before d
60 could have tacrolimus tapered in the absence of
VHD. In addition, a methotrexate 5 mg/m2 intra-
enous push was given on d 1, d 3, and d 6.
ethotrexate was held in the event of a serum creat-
nine level 3.0 mg/dL and administered with leuco-
orin 10 mg IV every 6 hours for 4 doses if the serum
reatinine level was 2.0-2.9 mg/dL.
upportive Care
Patients with a history of herpes simplex infection
r seropositivity received acyclovir 200-400 mg orally
times a day or valacyclovir 500 mg orally 1 time daily
rom d 3 to d 100. Fungal prophylaxis was under-
aken with ﬂuconazole or itraconazole 200-400 mg arally daily, voriconazole 200 mg orally 2 times daily,
r low-dose amphotericin B (10-20 mg/day) on d 1
hrough d 100. Pneumocystis carinii pneumonia pro-
hylaxis consisted of a trimethoprim-sulfamethox-
zole (Bactrim, Roche, Nutley, NJ) double-strength
ablet orally 2 times daily for 2 days weekly on d 3
hrough d 100. Patients with sulfa allergies could
eceive dapsone 100 mg orally 3 times a week or
nhaled pentamidine. All prophylaxis could be ex-
ended beyond d100 at the discretion of the treating
hysician. No prophylaxis for cytomegalovirus (CMV)
as initiated. Surveillance for CMV was undertaken
hrough detection of CMV antigen by polymerase
hain reaction or enzyme-linked immunosorbent as-
ay weekly  8 beginning on d 7, every other week
ntil d 98, and then as needed. Patients with CMV
etected (positive CMV cultures or CMV antigen)
eceived gancyclovir 5 mg/kg IV 2 times daily 14 days.
anagement of acute and chronic GVHDs (ie, man-
gement of immunosuppressant medications) was at
he discretion of the treating physician.
onor Lymphocyte Infusion
Patients were eligible for up to 2 DLIs if they
emonstrated disease progression while off all immu-
osuppression for 30 days without signs or symp-
oms of active GVHD. Patients received 1  107
D3 cells/kg from the original HLA-identical sib-
ing donor (from initial stem cell collection or through
epeat leukapheresis). Patients with further disease
rogression were eligible for a second DLI of 5  107
D3 cells/kg no sooner than 8 weeks after the ﬁrst
LI. No post-DLI immunosuppression was given.
atients with disease progression after the second DLI
ere eligible to receive interferon-, escalated from 1
illion unit 3 times a week to a maximum of 9 million
nits 3 times a week.
atient Assessment
All patients underwent computed tomography
f the chest, abdomen, and pelvis and bone scanning
ithin 28 days before registration. Computed to-
ography was repeated at d 60, d 120, d 180,
nd every 3 months thereafter. Bone scanning was
epeated at the time of computed tomography only
n patients with bone metastases or in patients who
eveloped signs or symptoms of bone metastases
hile in the study. Donor chimerism for T cells
CD3), myeloid cells (CD14/15), and B cells
CD19) was assessed through ampliﬁcation of in-
ormative variable number of tandem repeat or
hort tandem repeat domains on d 30, d 60, d
90, d 120, d 180, and every 3 months there-fter.
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Allogeneic Transplantation in Renal Carcinoma 781tatistical Design and Data Analysis
Sample size calculation was based on the primary
ndpoint (response rate). The null hypothesis was that
he response rate (complete and partial remission) was
20% versus the alternative hypothesis that the re-
ponse rate (complete and partial remission) was
40%. A single-stage design was used in which 36
atients with RCC would be accrued. This design had
type I error rate of .09 and 91% power. Patient
egistration and data collection were managed by the
ancer and Leukemia Group B Statistical Center.
ata quality was ensured by careful review of data by
ALGB Statistical Center staff and by the study
hairperson.
In addition, the study was monitored for unaccept-
ble toxicity, deﬁned as transplant-related mortality
ithin the ﬁrst 6 months after transplantation. In
articular, if at any time during the course of the
tudy, the observed percentage of transplant-related
able 2. Patient Characteristics (n  22)
ge (y)* 53 (39-60)
ale† 16 (73%)
emale† 6 (27%)
COG performance status†
0 14 (64%)
1 8 (36%)
ite of metastases‡
Lung 14 (64%)
Lymph node 15 (68%)
Liver 5 (23%)
Bone 11 (50%)
etastatic sites§
1 6 (27%)
2 6 (27%)
>3 10 (45%)
rior local therapy‡
Nephrectomy 21 (95%)
Radiotherapy (any) 13 (59%)
rior systemic treatments§
1 13 (59%)
2 7 (32%)
>3 1 (5%)
ears from diagnosis to treatment 1.5 (.7-2.1)
aseline hemoglobin (g/dL) 13.9 (9.0-16.1)
aseline LDH (U/dL) 177 (129-258)
COG indicates ??; LDH, lactate dehydrogenase.
Median (range).
Number of patients (%).
Categories are not mutually exclusive.
Number (%).
Median (interquartile range).
able 3. Engraftment
T Cells (
edian (range) donor chimerism at day 30 94% (74%
edian (range) donor chimerism at day 90 98% (35%
edian time to >90% chimerism Day 
edian time to >95% chimerism Day 60ortality exceeded 20% by 1 SE, accrual was to be
mmediately suspended. Survival time was calculated
s the difference between the last follow-up date or
ate of death and the date of initiation of treatment on
rial. Progression-free survival was deﬁned as the in-
erval between date of progression or death, which-
ver occurred ﬁrst, and the date of treatment initia-
ion. Overall survival and progression-free survival
istributions were estimated with the Kaplan-Meier
roduct-limit method.
ESULTS
atient Characteristics
Between July 25, 2002 and April 5, 2004, 22 pa-
ients with metastatic RCC were enrolled at 14 insti-
utions. After accrual of 22 patients, no objective re-
ponse had been observed, and thus a futility analysis
as performed. Because it was deemed unlikely, based
n the results of this futility analysis, to accept the
lternative hypothesis, the study was closed to further
ccrual. Most patients (64%) had an ECOG perfor-
ance status 0 and 95% had undergone previous ne-
hrectomy (Table 2). A substantial proportion of pa-
ients had received previous radiotherapy (59%)
nd/or had received 2 previous systemic regimens
or metastatic RCC (37%). In addition, the median
ime from diagnosis of RCC to protocol therapy was
hort (1.5 years).
ngraftment
A median of 5.2  106 (range, 2.6-12.8  106)
D34 cells/kg and a median of 3.3  106 (range,
.4-7.5  106) CD3 cells/kg were infused. Median
ime to neutrophil recovery 1000/L was 12 days
range, 3-32). Median time to untransfused platelet
ecovery 50 000/L was 15 days (range, 8-26). En-
raftment data for major lineages are presented in
able 3. Nineteen patients were successfully tapered
ff tacrolimus per protocol. By d120, 17 (89%; 95%
onﬁdence interval [CI], 67%-99%) of evaluable pa-
ients had achieved 90% donor T-cell chimerism
nd 16 patients (84%; 95% CI, 60%-97%) had
chieved 95% donor T-cell chimerism. Engrafting
ailed in 1 patient who had autologous bone marrow
ecovery.
Myeloid Cells (CD14/15) B Cells (CD19)
56% (14%-100%) 87% (65%-100%)
51% (5%-100%) 79% (7%-100%)
Day 75 Day 90CD3)
-100%)
-100%)
30Day 75 Day 105
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B. I. Rini et al782linical Outcomes
All 22 patients were evaluable for response, toxic-
ty, and survival. No RECIST-deﬁned objective re-
ponses were observed in 22 evaluable patients at any
valuation timepoints. Seventeen patients died, 15 pa-
ients died of disease progression, 1 of sepsis, and 1 of
iver failure secondary to extensive GVHD. The re-
aining 5 patients are alive, 2 with stable disease and
with disease progression. Median progression-free
urvival was 3.0 months (95% CI, 2.3-4.2 months;
igure 1) and median overall survival was 5.5 months
95% CI, 3.9-12.0 months; Figure 2). DLI and subse-
uent interferon were administered to 2 patients; neither
ad an objective disease response or signiﬁcant toxicity.
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Figure 1. Kaplan-Meier progression-free survFigure 2. Kaplan-Meier overall survival for patihe remaining patients were ineligible for DLI inter-
eron because of rapid progression of disease or persis-
ence of GVHD, which excluded patients from these
aneuvers per protocol.
oxicity
Acute toxicity was as expected from an N-SCT reg-
men, with typical myelosuppresion and grade 3 febrile
eutropenia in 4 patients. Maximum grade 2 overall
ematologic toxicity observed was grade 3 in 2 patients
nd grade 4 in 16 patients. Maximum nonhematologic
oxicity observed was grade 3 in 8 patients, grade 4 in 8
atients, and grade 5 in 2 patients. Regimen-related
ortality was reported in 2 of 22 patients (9%; 95%
14 16 18 20 22 24 26 28 30
urvival (months)
4 4 3 3 2 2 1 1
14 16 18 20 22 24 26 28 30
ree Survival  (months)
2 2 1 1 1 1
patients with metastatic RCC after N-SCT.12
verall S
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3ents with metastatic RCC after N-SCT.
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Allogeneic Transplantation in Renal Carcinoma 783I, 1%-29%), with 1 death from sepsis and 1 death
rom liver failure due to chronic GVHD.
Acute GVHD was observed in 11 patients (50%;
5% CI, 28%-72%) and was grade 2 in 4 patients
18%) and grade 3 in 3 patients (14%; Table 4). Acute
VH consisted of rash, diarrhea, and increased bili-
ubin. Chronic GVHD was observed in 5 patients.
hronic GVHD was limited in 3 patients and exten-
ive in 2 patients. Of the 2 patients with extensive
hronic GVHD, 1 died from liver failure and the
ther is alive with stable disease and ongoing chronic
VHD.
ISCUSSION
Based on previous studies of allogeneic SCT in
etastatic RCCs demonstrating an antitumor effect, a
ulti-institutional study of this approach was under-
aken to more accurately deﬁne the relative risks and
eneﬁts. No objective response was observed in this
ohort. Toxicity included acute and chronic forms of
VHD with a 9% transplant-related mortality rate.
This study demonstrated that allogeneic SCT for
etastatic RCC is feasible in a multi-institutional set-
ing. Transplantation of solid tumors is unique from
ematologic malignancies because it requires coordi-
ation between the solid tumor specialist, who may
ot otherwise have transplantation expertise, and the
ransplantation physician, who may not routinely care
or patients with RCC. Thus, selection of patients
ith appropriate RCC disease features and timely
elivery of N-SCT is paramount. Enrollment restric-
ion to centers with expertise in RCC and transplan-
ation allowed for successful evaluation of this ap-
roach in RCC. Nevertheless, inherent delays in the
ransplantation process including insurance approval
nd coordination of care may have resulted in wors-
ning of disease before N-SCT and thus affected
utcome. In addition, a substantial percentage of pa-
ients in this study had features of poor prognosis for
CC including previous radiotherapy, multiple sites
f disease including hepatic metastases, multiple pre-
ious systemic treatment regimens, and a worse per-
ormance status compared with single-institution
able 4. Graft-versus-Host Disease (n  22)
Patients, n (%)
cute GVHD 11 (50%)
Grade 1 4 (18%)
Grade 2 4 (18%)
Grade 3 3 (14%)
Grade 4 0 (0%)
hronic GVHD 5 (23%)
Limited 3 (14%)
Extensive 2 (9%)tudies of N-SCT in RCC. Although complete data to tharacterize this cohort as reported for previously
reated patients with metastatic RCC [17] was not
vailable and direct comparison with other study co-
orts is imprecise, the adverse features noted above
ay have decreased the ability to observe an antitu-
or effect from this therapy. The extremely short
edian progression-free and overall survivals ob-
erved for this cohort may reﬂect a patient group with
poor prognosis regardless of treatment. Lack of an
bserved antitumor effect thus highlights the appro-
riate but extreme selection of patients in previous
ingle-institution studies and emphasizes the limited
eneral applicability of this approach.
Because T cells are thought to mediate the graft-
ersus-renal cancer effect of N-SCT, establishment of
donor T-cell graft is required to allow for an anti-
umor effect before disease progression. Early and
dequate donor T-cell engraftment was achieved in
his study as manifest by chimerism assays and obser-
ation of GVHD. The GVHD prophylaxis regimen
tacrolimus and mini-methotrexate) is considered
oderately immunosuppressive. Alternative, less im-
unosuppressive regimens could have resulted in
ore GVHD and possibly a greater GVT effect.
owever, most patients on this study developed acute
nd/or chronic GVHD without a signiﬁcant GVT
ffect. Thus, the role of patient selection and a differ-
nt therapeutic approach may be more important than
egree of GVHD prophylactic immunosuppression.
revious series have noted acute and chronic GVHD
n most, but not all, patients who develop tumor
egression. Thus, separation of T cells directed
gainst self versus tumor antigens would be a critical
rst step in favorably affecting the balance of risk and
eneﬁt of N-SCT in RCC. Further, recent in vitro
ata have suggested enhanced cytotoxicity against
CC cell lines using allogeneic killer immunoglobu-
in-like receptor–incompatible natural killer cells [18].
s further reﬁnement of N-SCT for RCC is a rea-
onable investigative endeavor, a greater understand-
ng of the speciﬁc cells mediating the GVT effect
ould allow for more efﬁcient and safe application of
his approach in RCC.
This study has several limitations. Patients were
ot as highly selected in terms of performance status,
umor burden, or pace of disease progression as in
ingle-institution studies. Although this may have de-
reased the antitumor effect, such patients are more
epresentative of the RCC population at large. Previ-
us large studies of patients with metastatic RCC have
dentiﬁed several factors as prognostic of outcome
17,19-21]. It is clear that patient selection, especially
n single-arm phase II trials, can heavily inﬂuence
esults. Patients selected for transplantation should be
imited to those without adverse prognostic features.
uch patient selection, which was not undertaken in
his trial, will be paramount if this modality is to be
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B. I. Rini et al784urther investigated in RCC. Further, central histo-
ogic review was not undertaken to ensure clear cell
istology; thus, inclusion of patients with non–clear
ell histology could have diluted the antitumor effect.
ata published subsequent to the design of this trial
ave indicated that the vast majority of responders to
-SCT in RCC have clear cell histology. Moreover,
anagement of a GVH response was left to the dis-
retion of the treating physician. Currently, a balance
etween GVH and GVT effects may be delicate, and
ariable handling of immunosuppressive regimens
ould have affected outcome.
The clinical necessity of this high-risk approach
as also lessened recently. Approaches targeting vas-
ular endothelial growth factor in metastatic RCC
ave demonstrated substantial clinical activity with
cceptable safety proﬁles [22-24]. These approaches
re likely to assume a signiﬁcant role in the therapy of
dvanced RCC. In addition, the modest activity of
ytokines will continue their use in advanced RCC.
hus, the risk-beneﬁt proﬁle of N-SCT in RCC
ould relegate this approach to patients refractory to
hese treatments, potentially diminishing the suitabil-
ty of such patients for transplantation and lessening
he chance of observing an antitumor effect. In sum-
ary, a GVT effect was not observed in this study
espite acute and chronic GVHDs, thus highlighting
he need for further understanding of this approach.
llogeneic SCT remains investigational in RCC.
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